Utility of DNA methylation markers for diagnosing cancer

International Journal of Surgery

Volumn 8, Issue 3, 2010, Pages 194-198

  Qureshi, Sohail A ^a   Bashir, Muhammed Umair ^a   Yaqinuddin, Ahmed ^b  

^a AGA KHAN UNIVERSITY MEDICAL COLLEGE   (Pakistan)

^b ALFAISAL UNIVERSITY   (Saudi Arabia)

Author keywords

Biomarker; Cancer; DNA methylation

Indexed keywords

DNA METHYLTRANSFERASE; GENOMIC DNA;

BODY FLUID; CANCER DIAGNOSIS; CPG ISLAND; DNA METHYLATION; GENE EXPRESSION REGULATION; HUMAN; MICROARRAY ANALYSIS; ONCOGENE; PRIORITY JOURNAL; PROMOTER REGION; REVIEW; TUMOR SUPPRESSOR GENE;

CPG ISLANDS; DNA METHYLATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC MARKERS; HUMANS; NEOPLASMS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEINS;

EID: 77950595010     PISSN: 17439191     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijsu.2010.02.001     Document Type: Review

References (74)

1. Laird P.W. The power and the promise of DNA methylation markers. Nat Rev Cancer 3 (2003) 253-266
2. Yaqinuddin A., Abbas F., Naqvi S.Z., Bashir M.U., Qazi R., and Qureshi S.A. Silencing of MBD1 and MeCP2 in prostate-cancer-derived PC3 cells produces differential gene expression profiles and cellular phenotypes. Biosci Rep 28 (2008) 319-326
3. Yaqinuddin A., Qureshi S.A., Qazi R., and Abbas F. Down-regulation of DNMT3b in PC3 cells effects locus-specific DNA methylation, and represses cellular growth and migration. Cancer Cell Int 8 (2008) 13
4. Yaqinuddin A., Qureshi S.A., Qazi R., Farooq S., and Abbas F. DNMT1 silencing affects locus specific DNA methylation and increases prostate cancer derived PC3 cell invasiveness. J Urol 182 (2009) 756-761
5. Reik W., Dean W., and Walter J. Epigenetic reprogramming in mammalian development. Science 293 (2001) 1089-1093
6. Monk M., Boubelik M., and Lehnert S. Temporal and regional changes in DNA methylation in the embryonic, extraembryonic and germ cell lineages during mouse embryo development. Development 99 (1987) 371-382
7. Issa J.P. CpG-island methylation in aging and cancer. Curr Top Microbiol Immunol 249 (2000) 101-118
8. Tang W.Y., and Ho S.M. Epigenetic reprogramming and imprinting in origins of disease. Rev Endocr Metab Disord 8 (2007) 173-182
9. Abdolmaleky H.M., Cheng K.H., Faraone S.V., Wilcox M., Glatt S.J., Gao F., et al. Hypomethylation of MB-COMT promoter is a major risk factor for schizophrenia and bipolar disorder. Hum Mol Genet 15 (2006) 3132-3145
10. Deng C., Kaplan M.J., Yang J., Ray D., Zhang Z., McCune W.J., et al. Decreased Ras-mitogen-activated protein kinase signaling may cause DNA hypomethylation in T lymphocytes from lupus patients. Arthritis Rheum 44 (2001) 397-407
11. Samaco R.C., Hogart A., and LaSalle J.M. Epigenetic overlap in autism-spectrum neurodevelopmental disorders: MECP2 deficiency causes reduced expression of UBE3A and GABRB3. Hum Mol Genet 14 (2005) 483-492
12. Feinberg A.P., and Vogelstein B. Hypomethylation distinguishes genes of some human cancers from their normal counterparts. Nature 301 (1983) 89-92
13. Weber M., Davies J.J., Wittig D., Oakeley E.J., Haase M., Lam W.L., et al. Chromosome-wide and promoter-specific analyses identify sites of differential DNA methylation in normal and transformed human cells. Nat Genet 37 (2005) 853-862
14. Fraga M.F., Herranz M., Espada J., Ballestar E., Paz M.F., Ropero S., et al. A mouse skin multistage carcinogenesis model reflects the aberrant DNA methylation patterns of human tumors. Cancer Res 64 (2004) 5527-5534
15. Bestor T.H. Transposons reanimated in mice. Cell 122 (2005) 322-325
16. Cui J., Rohr L.R., Swanson G., Speights V.O., Maxwell T., and Brothman A.R. Hypermethylation of the caveolin-1 gene promoter in prostate cancer. Prostate 46 (2001) 249-256
17. Eden A., Gaudet F., Waghmare A., and Jaenisch R. Chromosomal instability and tumors promoted by DNA hypomethylation. Science 300 (2003) 455
18. Greger V., Passarge E., Hopping W., Messmer E., and Horsthemke B. Epigenetic changes may contribute to the formation and spontaneous regression of retinoblastoma. Hum Genet 83 (1989) 155-158
19. Gonzalez-Zulueta M., Bender C.M., Yang A.S., Nguyen T., Beart R.W., Van Tornout J.M., et al. Methylation of the 5' CpG island of the p16/CDKN2 tumor suppressor gene in normal and transformed human tissues correlates with gene silencing. Cancer Res 55 (1995) 4531-4535
20. Herman J.G., and Baylin S.B. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 349 (2003) 2042-2054
21. Esteller M., Sanchez-Cespedes M., Rosell R., Sidransky D., Baylin S.B., and Herman J.G. Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients. Cancer Res 59 (1999) 67-70
22. Kurakawa E., Shimamoto T., Utsumi K., Hirano T., Kato H., and Ohyashiki K. Hypermethylation of p16(INK4a) and p15(INK4b) genes in non-small cell lung cancer. Int J Oncol 19 (2001) 277-281
23. Liu Y., An Q., Li L., Zhang D., Huang J., Feng X., et al. Hypermethylation of p16INK4a in Chinese lung cancer patients: biological and clinical implications. Carcinogenesis 24 (2003) 1897-1901
24. Ng C.S., Zhang J., Wan S., Lee T.W., Arifi A.A., Mok T., et al. Tumor p16M is a possible marker of advanced stage in non-small cell lung cancer. J Surg Oncol 79 (2002) 101-106
25. Jahr S., Hentze H., Englisch S., Hardt D., Fackelmayer F.O., Hesch R.D., et al. DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res 61 (2001) 1659-1665
26. Goessl C., Muller M., Heicappell R., Krause H., and Miller K. DNA-based detection of prostate cancer in blood, urine, and ejaculates. Ann N Y Acad Sci 945 (2001) 51-58
27. Botezatu I., Serdyuk O., Potapova G., Shelepov V., Alechina R., Molyaka Y., et al. Genetic analysis of DNA excreted in urine: a new approach for detecting specific genomic DNA sequences from cells dying in an organism. Clin Chem 46 (2000) 1078-1084
28. Belinsky S.A., Palmisano W.A., Gilliland F.D., Crooks L.A., Divine K.K., Winters S.A., et al. Aberrant promoter methylation in bronchial epithelium and sputum from current and former smokers. Cancer Res 62 (2002) 2370-2377
29. Ahrendt S.A., Chow J.T., Xu L.H., Yang S.C., Eisenberger C.F., Esteller M., et al. Molecular detection of tumor cells in bronchoalveolar lavage fluid from patients with early stage lung cancer. J Natl Cancer Inst 91 (1999) 332-339
30. Evron E., Dooley W.C., Umbricht C.B., Rosenthal D., Sacchi N., Gabrielson E., et al. Detection of breast cancer cells in ductal lavage fluid by methylation-specific PCR. Lancet 357 (2001) 1335-1336
31. Krassenstein R., Sauter E., Dulaimi E., Battagli C., Ehya H., Klein-Szanto A., et al. Detection of breast cancer in nipple aspirate fluid by CpG island hypermethylation. Clin Cancer Res 10 (2004) 28-32
32. Muller H.M., Oberwalder M., Fiegl H., Morandell M., Goebel G., Zitt M., et al. Methylation changes in faecal DNA: a marker for colorectal cancer screening?. Lancet 363 (2004) 1283-1285
33. Rosas S.L., Koch W., da Costa Carvalho M.G., Wu L., Califano J., Westra W., et al. Promoter hypermethylation patterns of p16, O6-methylguanine-DNA-methyltransferase, and death-associated protein kinase in tumors and saliva of head and neck cancer patients. Cancer Res 61 (2001) 939-942
34. Chan M.W., Chan L.W., Tang N.L., Tong J.H., Lo K.W., Lee T.L., et al. Hypermethylation of multiple genes in tumor tissues and voided urine in urinary bladder cancer patients. Clin Cancer Res 8 (2002) 464-470
35. Palmisano W.A., Divine K.K., Saccomanno G., Gilliland F.D., Baylin S.B., Herman J.G., et al. Predicting lung cancer by detecting aberrant promoter methylation in sputum. Cancer Res 60 (2000) 5954-5958
36. Herman J.G., Graff J.R., Myohanen S., Nelkin B.D., Baylin S.B., and Methylation-specific P.C.R. a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci U S A 93 (1996) 9821-9826
37. Clark S.J., Harrison J., Paul C.L., and Frommer M. High sensitivity mapping of methylated cytosines. Nucleic Acids Res 22 (1994) 2990-2997
38. Frommer M., McDonald L.E., Millar D.S., Collis C.M., Watt F., Grigg G.W., et al. A genomic sequencing protocol that yields a positive display of 5-methylcytosine residues in individual DNA strands. Proc Natl Acad Sci U S A 89 (1992) 1827-1831
39. Xiong Z., and Laird P.W. COBRA: a sensitive and quantitative DNA methylation assay. Nucleic Acids Res 25 (1997) 2532-2534
40. Eads C.A., Danenberg K.D., Kawakami K., Saltz L.B., Blake C., Shibata D., et al. MethyLight: a high-throughput assay to measure DNA methylation. Nucleic Acids Res 28 (2000) E32
41. Trinh B.N., Long T.I., and Laird P.W. DNA methylation analysis by MethyLight technology. Methods 25 (2001) 456-462
42. Schumacher A., Weinhausl A., and Petronis A. Application of microarrays for DNA methylation profiling. Methods Mol Biol 439 (2008) 109-129
43. Zilberman D., and Henikoff S. Genome-wide analysis of DNA methylation patterns. Development 134 (2007) 3959-3965
44. Lee S., Hwang K.S., Lee H.J., Kim J.S., and Kang G.H. Aberrant CpG island hypermethylation of multiple genes in colorectal neoplasia. Lab Invest 84 (2004) 884-893
45. Malkhosyan S.R., Yamamoto H., Piao Z., and Perucho M. Late onset and high incidence of colon cancer of the mutator phenotype with hypermethylated hMLH1 gene in women. Gastroenterology 119 (2000) 598
46. Xu X.L., Yu J., Zhang H.Y., Sun M.H., Gu J., Du X., et al. Methylation profile of the promoter CpG islands of 31 genes that may contribute to colorectal carcinogenesis. World J Gastroenterol 10 (2004) 3441-3454
47. Liu Y.N., Liu Y., Lee H.J., Hsu Y.H., and Chen J.H. Activated androgen receptor downregulates E-cadherin gene expression and promotes tumor metastasis. Mol Cell Biol 28 (2008) 7096-7108
48. Mirza S., Sharma G., Prasad C.P., Parshad R., Srivastava A., Gupta S.D., et al. Promoter hypermethylation of TMS1, BRCA1, ERalpha and PRB in serum and tumor DNA of invasive ductal breast carcinoma patients. Life Sci 81 (2007) 280-287
49. Licchesi J.D., Westra W.H., Hooker C.M., and Herman J.G. Promoter hypermethylation of hallmark cancer genes in atypical adenomatous hyperplasia of the lung. Clin Cancer Res 14 (2008) 2570-2578
50. Yu Z.H., Wang Y.C., Chen L.B., Song Y., Liu C., Xia X.Y., et al. [Analysis of RASSF1A promoter hypermethylation in serum DNA of non-small cell lung cancer]. Zhonghua Zhong Liu Za Zhi 30 (2008) 284-287
51. Alonso M.E., Bello M.J., Gonzalez-Gomez P., Arjona D., de Campos J.M., Gutierrez M., et al. Aberrant CpG island methylation of multiple genes in ependymal tumors. J Neurooncol 67 (2004) 159-165
52. Uhlmann K., Rohde K., Zeller C., Szymas J., Vogel S., Marczinek K., et al. Distinct methylation profiles of glioma subtypes. Int J Cancer 106 (2003) 52-59
53. Esteller M. Profiling aberrant DNA methylation in hematologic neoplasms: a view from the tip of the iceberg. Clin Immunol 109 (2003) 80-88
54. Ropero S., Setien F., Espada J., Fraga M.F., Herranz M., Asp J., et al. Epigenetic loss of the familial tumor-suppressor gene exostosin-1 (EXT1) disrupts heparan sulfate synthesis in cancer cells. Hum Mol Genet 13 (2004) 2753-2765
55. Zhao Y., Yu L., Wang Q.S., Li H.H., Bo J., Wang S.H., et al. [Id4 gene methylation for detection of minimal residual disease in acute leukemia]. Zhonghua Xue Ye Xue Za Zhi 27 (2006) 298-301
56. Gallardo F., Esteller M., Pujol R.M., Costa C., Estrach T., and Servitje O. Methylation status of the p15, p16 and MGMT promoter genes in primary cutaneous T-cell lymphomas. Haematologica 89 (2004) 1401-1403
57. van Doorn R., Zoutman W.H., Dijkman R., de Menezes R.X., Commandeur S., Mulder A.A., et al. Epigenetic profiling of cutaneous T-cell lymphoma: promoter hypermethylation of multiple tumor suppressor genes including BCL7a, PTPRG, and p73. J Clin Oncol 23 (2005) 3886-3896
58. Jarmalaite S., Jankevicius F., Kurgonaite K., Suziedelis K., Mutanen P., and Husgafvel-Pursiainen K. Promoter hypermethylation in tumour suppressor genes shows association with stage, grade and invasiveness of bladder cancer. Oncology 75 (2008) 145-151
59. Herman J.G., Latif F., Weng Y., Lerman M.I., Zbar B., Liu S., et al. Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. Proc Natl Acad Sci U S A 91 (1994) 9700-9704
60. Reibenwein J., Pils D., Horak P., Tomicek B., Goldner G., Worel N., et al. Promoter hypermethylation of GSTP1, AR, and 14-3-3sigma in serum of prostate cancer patients and its clinical relevance. Prostate 67 (2007) 427-432
61. Smeds J., Berggren P., Ma X., Xu Z., Hemminki K., and Kumar R. Genetic status of cell cycle regulators in squamous cell carcinoma of the oesophagus: the CDKN2A (p16(INK4a) and p14(ARF)) and p53 genes are major targets for inactivation. Carcinogenesis 23 (2002) 645-655
62. Kim T.Y., Jong H.S., Jung Y., Kang G.H., and Bang Y.J. DNA hypermethylation in gastric cancer. Aliment Pharmacol Ther 20 Suppl. 1 (2004) 131-142
63. Chang H., Yi B., Li L., Zhang H.Y., Sun F., Dong S.Q., et al. Methylation of tumor associated genes in tissue and plasma samples from liver disease patients. Exp Mol Pathol 85 (2008) 96-100
64. Tchou J.C., Lin X., Freije D., Isaacs W.B., Brooks J.D., Rashid A., et al. GSTP1 CpG island DNA hypermethylation in hepatocellular carcinomas. Int J Oncol 16 (2000) 663-676
65. Wilcox C.B., Baysal B.E., Gallion H.H., Strange M.A., and DeLoia J.A. High-resolution methylation analysis of the BRCA1 promoter in ovarian tumors. Cancer Genet Cytogenet 159 (2005) 114-122
66. Bachman K.E., Herman J.G., Corn P.G., Merlo A., Costello J.F., Cavenee W.K., et al. Methylation-associated silencing of the tissue inhibitor of metalloproteinase-3 gene suggest a suppressor role in kidney, brain, and other human cancers. Cancer Res 59 (1999) 798-802
67. Banelli B., Gelvi I., Di Vinci A., Scaruffi P., Casciano I., Allemanni G., et al. Distinct CpG methylation profiles characterize different clinical groups of neuroblastic tumors. Oncogene 24 (2005) 5619-5628
68. Domann F.E., Rice J.C., Hendrix M.J., and Futscher B.W. Epigenetic silencing of maspin gene expression in human breast cancers. Int J Cancer 85 (2000) 805-810
69. Jarrard D.F., Kinoshita H., Shi Y., Sandefur C., Hoff D., Meisner L.F., et al. Methylation of the androgen receptor promoter CpG island is associated with loss of androgen receptor expression in prostate cancer cells. Cancer Res 58 (1998) 5310-5314
70. Jones P.A., Wolkowicz M.J., Rideout III W.M., Gonzales F.A., Marziasz C.M., Coetzee G.A., et al. De novo methylation of the MyoD1 CpG island during the establishment of immortal cell lines. Proc Natl Acad Sci U S A 87 (1990) 6117-6121
71. Sakai T., Toguchida J., Ohtani N., Yandell D.W., Rapaport J.M., and Dryja T.P. Allele-specific hypermethylation of the retinoblastoma tumor-suppressor gene. Am J Hum Genet 48 (1991) 880-888
72. Salem C.E., Markl I.D., Bender C.M., Gonzales F.A., Jones P.A., and Liang G. PAX6 methylation and ectopic expression in human tumor cells. Int J Cancer 87 (2000) 179-185
73. Salvesen H.B., MacDonald N., Ryan A., Jacobs I.J., Lynch E.D., Akslen L.A., et al. PTEN methylation is associated with advanced stage and microsatellite instability in endometrial carcinoma. Int J Cancer 91 (2001) 22-26
74. Tsuchiya T., Tamura G., Sato K., Endoh Y., Sakata K., Jin Z., et al. Distinct methylation patterns of two APC gene promoters in normal and cancerous gastric epithelia. Oncogene 19 (2000) 3642-3646